The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

Posted by: | January 10, 2018 | Comments

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

ABSTRACT

Anti–PD-1–based immunotherapy has had a major impact on cancer treatment but has only benefited a subset of patients. Among the variables that could contribute to interpatient heterogeneity is differential composition of the patients’ microbiome, which has been shown to affect antitumor immunity and immunotherapy efficacy in preclinical mouse models. We analyzed baseline stool samples from metastatic melanoma patients before immunotherapy treatment, through an integration of 16S ribosomal RNA gene sequencing, metagenomic shotgun sequencing, and quantitative polymerase chain reaction for selected bacteria.

Read more at: Science

Vyara Matson, Jessica Fessler, Riyue Bao, Tara Chongsuwat, Yuanyuan Zha, Maria-Luisa Alegre, Jason J. Luke, Thomas F. Gajewski. DOI: 10.1126/science.aao3290. 05 Jan 2018.





Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required



Terms & Conditions | Privacy Policy | © 2016 The Translational Microbiome Research Forum